Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

573 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.
Boekel L, Stalman EW, Wieske L, Hooijberg F, van Dam KPJ, Besten YR, Kummer LYL, Steenhuis M, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Parra Sanchez A, van Els CACM, de Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart CF, Teng YKO, van Paassen P, Busch MH, Jallah PBP, Brusse E, van Doorn PA, Baars AE, Hijnen DJ, Schreurs CRG, van der Pol WL, Goedee HS, Vogelzang EH, Leeuw M, Atiqi S, van Vollenhoven R, Gerritsen M, van der Horst-Bruinsma IE, Lems WF, Nurmohamed MT, Boers M, Keijzer S, Keijser J, van de Sandt C, Boogaard A, Cristianawati O, Ten Brinke A, Verstegen NJM, Zwinderman KAH, van Ham SM, Rispens T, Kuijpers TW, Wolbink G, Eftimov F; T2B! immunity against SARS-CoV-2 study group. Boekel L, et al. Among authors: boers m. Lancet Rheumatol. 2022 Apr 29. doi: 10.1016/S2665-9913(22)00102-3. Online ahead of print. Lancet Rheumatol. 2022. PMID: 35527808 Free PMC article.
Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study.
Boekel L, Hooijberg F, Vogelzang EH, Besten YR, Leeuw M, Atiqi S, van Vollenhoven RF, Wijbrandts CA, Gerritsen M, Krieckaert C, Dijkshoorn B, Bakhlakh S, Crooijmans JJ, Voskuyl A, van der Horst-Bruinsma IE, Lems W, Kuijpers TW, van Ham SM, Wieske L, Eftimov F, Kummer LY, van Dam PK, Stalman EW, Steenhuis M, Keijzer S, Cristianawati O, Keijser J, Loeff FC, Tas SW, Nurmohamed MT, Boers M, Rispens T, Wolbink G. Boekel L, et al. Among authors: boers m. RMD Open. 2022 Apr;8(1):e002035. doi: 10.1136/rmdopen-2021-002035. RMD Open. 2022. PMID: 35383121 Free PMC article.
The HOME Core outcome set for clinical trials of atopic dermatitis.
Williams HC, Schmitt J, Thomas KS, Spuls PI, Simpson EL, Apfelbacher CJ, Chalmers JR, Furue M, Katoh N, Gerbens LAA, Leshem YA, Howells L, Singh JA, Boers M; HOME Initiative. Williams HC, et al. Among authors: boers m. J Allergy Clin Immunol. 2022 Mar 26:S0091-6749(22)00389-X. doi: 10.1016/j.jaci.2022.03.017. Online ahead of print. J Allergy Clin Immunol. 2022. PMID: 35351441 Free article.
Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial.
Ruwaard J, L' Ami MJ, Kneepkens EL, Krieckaert C, Nurmohamed MT, Hooijberg F, van Kuijk A, van Denderen JC, Burgemeister L, Rispens T, Boers M, Wolbink GJ. Ruwaard J, et al. Among authors: boers m. Scand J Rheumatol. 2022 Mar 2:1-8. doi: 10.1080/03009742.2022.2028364. Online ahead of print. Scand J Rheumatol. 2022. PMID: 35234569
573 results